Renal accumulation of [111In]DOTATOC in rats: Influence of inhibitors of the organic ion transport and diuretics

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 12, 2007, Pages 2129-2134

  Stahl, A R ^a,b   Wagner, B ^a   Poethko, T ^a   Perutka, M ^a   Wester, H J ^a   Essler, M ^a   Heemann, U ^a   Schwaiger, M ^a   Lutz, J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Kidney protection; Neuroendocrine tumour; Peptide receptor radionuclide therapy (PRRT); Somatostatin analogue

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTIDE IN 111; CIMETIDINE; DEXAMETHASONE; FUROSEMIDE; MANNITOL; PROBENECID; RADIOPHARMACEUTICAL AGENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG; 111IN DOTA TOC; 111IN-DOTA-TOC; DIAGNOSTIC AGENT; DIURETIC AGENT; DRUG DERIVATIVE; OCTREOTIDE; ORGANIC ANION TRANSPORTER;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD; CONTROLLED STUDY; ION TRANSPORT; KIDNEY; KIDNEY CORTEX; KIDNEY MEDULLA; LIVER; MALE; MUSCLE; NONHUMAN; PANCREAS; RAT; SPLEEN; ANIMAL; ANTIBODY SPECIFICITY; DRUG ANTAGONISM; DRUG EFFECT; FISCHER 344 RAT; METABOLIC CLEARANCE RATE; METABOLISM; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; DIURETICS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; OCTREOTIDE; ORGAN SPECIFICITY; ORGANIC ANION TRANSPORTERS; RADIOPHARMACEUTICALS; RATS; RATS, INBRED F344; TISSUE DISTRIBUTION;

EID: 36749042000     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0519-x     Document Type: Article

References (15)

1. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610-616.
2. Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med 2001;28:1552-1554.
3. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005;46(Suppl 1):83S-91S.
4. de Jong M, Barone R, Krenning E, Bernard B, Melis M, Visser T, et al. Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide. J Nucl Med 2005;46:1696-1700.
5. Cohen EP, Robbins ME. Radiation nephropathy. Semin Nephrol 2003;23:486-499.
6. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. (86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)-a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510-518.
7. van Eerd JE, Vegt E, Wetzels JF, Russel FG, Masereeuw R, Corstens FH, et al. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med 2006;47:528-533.
8. Vegt E, Wetzels JF, Russel FG, Masereeuw R, Boerman OC, van Eerd JE, et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 2006;47:432-436.
9. de Jong M, Rolleman EJ, Bernard BF, Visser TJ, Bakker WH, Breeman WA, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996;37:1388-1392.
10. Tahara H, Kusuhara H, Endou H, Koepsell H, Imaoka T, Fuse E, et al. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther 2005;315:337-345.
11. Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Kobayashi Y, et al. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther 2002;301:797-802.
12. Schottelius M, Schwaiger M, Wester HJ. Rapid and high-yield solution phase synthesis of DOTA-Tyr3-octreotide and DOTA-Tyr3-octreotate using unprotected DOTA. Tetrahedron Lett 2003;44:2393-2396.
13. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9-15.
14. Shikano N, Kawai K, Flores LG 2nd, Nishii R, Kubota N, Ishikawa N, et al. An artificial amino acid, 4-iodo-L-meta-tyrosine: biodistribution and excretion via kidney. J Nucl Med 2003;44:625-631.
15. Benet LZ. Pharmacokinetics/pharmacodynamics of furosemide in man: a review. J Pharmocokin Biopharm 1979;7:1-27.